Novo Nordisk's pricing procedures within the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of value gouging, stating the stark contrast amongst U.S. costs and those in Europe and copyright. Difficulties with diabetic retinopathy: Diabeti